Login to Your Account



'GABA GABA' DO? TOP-LINE DATA SAY YES

Placebo veto: Investors fang Alcobra phase III

By Randy Osborne
Staff Writer

Monday, October 6, 2014
The modified intent to treat phase III results with Alcobra Ltd.'s non-stimulant metadoxine extended release for ADHD in adults gave investors the jitters, but they may have been distracted by the exclusion of four high responders to placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription